Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

被引:502
作者
Ohren, JF
Chen, HF
Pavlovsky, A
Whitehead, C
Zhang, EL
Kuffa, P
Yan, CH
McConnell, P
Spessard, C
Banotai, C
Mueller, WT
Delaney, A
Omer, C
Sebolt-Leopold, J
Dudley, DT
Leung, IK
Flamme, C
Warmus, J
Kaufman, M
Barrett, S
Tecle, H
Hasemann, CA
机构
[1] Pfizer Global Res & Dev, Dept Discovery Technol, Ann Arbor, MI 48105 USA
[2] Pfizer Global Res & Dev, Dept Mol Sci & Technol, Ann Arbor, MI 48105 USA
[3] Pfizer Global Res & Dev, Dept Genom & Biotechnol, Chesterfield, MO 63017 USA
[4] Pfizer Global Res & Dev, Dept Chem, Ann Arbor, MI 48105 USA
关键词
D O I
10.1038/nsmb859
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
MEK1 and MEK2 are closely related, dual-specificity tyrosine/threonine protein kinases found in the Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway. Approximately 30% of all human cancers have a constitutively activated MAPK pathway, and constitutive activation of MEK1 results in cellular transformation. Here we present the X-ray structures of human MEK1 and MEK2, each determined as a ternary complex with MgATP and an inhibitor to a resolution of 2.4 Angstrom and 3.2 Angstrom, respectively. The structures reveal that MEK1 and MEK2 each have a unique inhibitor-binding pocket adjacent to the MgATP-binding site. The presence of the potent inhibitor induces several conformational changes in the unphosphorylated MEK1 and MEK2 enzymes that lock them into a closed but catalytically inactive species. Thus, the structures reported here reveal a novel, noncompetitive mechanism for protein kinase inhibition.
引用
收藏
页码:1192 / 1197
页数:6
相关论文
共 40 条
  • [1] AHN NG, 1991, J BIOL CHEM, V266, P4220
  • [2] IDENTIFICATION OF THE SITES IN MAP KINASE KINASE-1 PHOSPHORYLATED BY P74(RAF-1)
    ALESSI, DR
    SAITO, Y
    CAMPBELL, DG
    COHEN, P
    SITHANANDAM, G
    RAPP, U
    ASHWORTH, A
    MARSHALL, CJ
    COWLEY, S
    [J]. EMBO JOURNAL, 1994, 13 (07) : 1610 - 1619
  • [3] THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY
    BAILEY, S
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 : 760 - 763
  • [4] Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
  • [5] RIBBON MODELS OF MACROMOLECULES
    CARSON, M
    [J]. JOURNAL OF MOLECULAR GRAPHICS, 1987, 5 (02): : 103 - &
  • [6] The MEK1 proline-rich insert is required for efficient activation of the mitogen-activated protein kinases ERK1 and ERK2 in mammalian cells
    Dang, A
    Frost, JA
    Cobb, MH
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (31) : 19909 - 19913
  • [7] Specificity and mechanism of action of some commonly used protein kinase inhibitors
    Davies, SP
    Reddy, H
    Caivano, M
    Cohen, P
    [J]. BIOCHEMICAL JOURNAL, 2000, 351 (351) : 95 - 105
  • [8] Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
    deAzevedo, WF
    MuellerDieckmann, HJ
    SchulzeGahmen, U
    Worland, PJ
    Sausville, E
    Kim, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) : 2735 - 2740
  • [9] CRYSTAL-STRUCTURE OF CYCLIN-DEPENDENT KINASE-2
    DEBONDT, HL
    ROSENBLATT, J
    JANCARIK, J
    JONES, HD
    MORGAN, DO
    KIM, SH
    [J]. NATURE, 1993, 363 (6430) : 595 - 602
  • [10] Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352
    Delaney, AM
    Printen, JA
    Chen, HF
    Fauman, EB
    Dudley, DT
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (21) : 7593 - 7602